The administration of cirmtuzumab (anti-ROR1) was shown to block gene expression signatures associated with stemness and effectively inhibit ROR1 signaling in patients with CLL [305]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.